CELC

SEC source: 0001688319-25-000010 · form4-12032025_091250.xml · nonDerivative · entry 2

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,260

F2 · price: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $98.010 to $98.505, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001688319-25-000010 · form4-12032025_091250.xml · nonDerivative · entry 1

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 8,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001296457-25-000004 · form4-11242025_091156.xml · nonDerivative · entry 1

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Brightstone Venture Capital Fund, LP

Disclosed balance after: 110,000

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.03, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reporting person is the General Partner of Brightstone.

SEC source: 0001688319-25-000007 · form4-11212025_091128.xml · derivative · entry 5

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 2,622

Underlying: Common Stock · 3,900 shares

Expires 2034-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 100% vested.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001688319-25-000007 · form4-11212025_091128.xml · nonDerivative · entry 3

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,260

F2 · price: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $96.465 to $96.920, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001688319-25-000007 · form4-11212025_091128.xml · nonDerivative · entry 2

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 11,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001688319-25-000007 · form4-11212025_091128.xml · nonDerivative · entry 1

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,260

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001213869-25-000009 · form4-09152025_080922.xml · derivative · entry 4

NIGON RICHARD · CIK 0001213869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,245 shares

Expires 2026-05-02

F1 · derivative.exercise_date: Currently exercisable.

SEC source: 0001213869-25-000009 · form4-09152025_080922.xml · derivative · entry 3

NIGON RICHARD · CIK 0001213869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,672 shares

Expires 2026-01-14

F1 · derivative.exercise_date: Currently exercisable.

SEC source: 0001213869-25-000009 · form4-09152025_080922.xml · nonDerivative · entry 2

NIGON RICHARD · CIK 0001213869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,010

SEC source: 0001213869-25-000009 · form4-09152025_080922.xml · nonDerivative · entry 1

NIGON RICHARD · CIK 0001213869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,765

SEC source: 0000950170-25-113977 · ownership.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,211,484

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $57.89 to $58.14, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-113977 · ownership.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 704,308

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $57.89 to $58.14, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000950170-25-113977 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,207,272

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Celcuity Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $56.215 to $56.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-113977 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 703,920

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Celcuity Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $56.215 to $56.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001415889-25-023644 · form4-09042025_080939.xml · derivative · entry 4

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 104,340 shares

Expires 2025-10-11

SEC source: 0001415889-25-023644 · form4-09042025_080939.xml · nonDerivative · entry 1

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,370,199

SEC source: 0001415889-25-022446 · form4-08202025_040801.xml · derivative · entry 2

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-08-18

F2 · derivative.exercise_date: Option vests in 1/4th increments upon Issuer's common stock achieving certain stock price performance milestones.

SEC source: 0001415889-25-022446 · form4-08202025_040801.xml · derivative · entry 1

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2035-08-18

F1 · derivative.exercise_date: 62,500 shares vest on 8/18/2026; the remaining 187,500 shares vest 1/36th per month thereafter.

SEC source: 0001415889-25-022447 · form4-08202025_040804.xml · derivative · entry 1

Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-08-18

F1 · derivative.exercise_date: 25,000 shares vest on 8/18/2026; the remaining 75,000 shares vest 1/36th per month thereafter.

SEC source: 0001415889-25-022448 · form4-08202025_040805.xml · derivative · entry 1

Hahne Vicky · CIK 0001716043 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2035-08-18

F1 · derivative.exercise_date: 20,000 shares vest on 8/18/2026; the remaining 60,000 shares vest 1/36th per month thereafter.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 7

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Brightstone Venture Capital Fund, LP

Disclosed balance after: 125,000

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F6 · ownership.nature: The reporting person is the General Partner of Brightstone.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 6

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Brightstone Venture Capital Fund, LP

Disclosed balance after: 129,141

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.99 to $45.76, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6 · ownership.nature: The reporting person is the General Partner of Brightstone.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 5

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Brightstone Venture Capital Fund, LP

Disclosed balance after: 145,579

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.97 to $44.96, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6 · ownership.nature: The reporting person is the General Partner of Brightstone.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 4

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Brightstone Venture Capital Fund, LP

Disclosed balance after: 167,956

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.94 to $43.90, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6 · ownership.nature: The reporting person is the General Partner of Brightstone.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 3

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.05 to $46.06, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 2

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,025

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.855, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020570 · form4-07302025_080741.xml · nonDerivative · entry 1

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,188

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Brightstone Venture Capital Fund, LP ("Brightstone") on December 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.99 to $44.96, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC") upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-014865 · form4-05292025_080532.xml · derivative · entry 4

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 6,522

Underlying: Common Stock · 6,522 shares

Expires 2034-06-04

F2 · derivative.exercise_date: 100% vested.

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001415889-25-014865 · form4-05292025_080532.xml · derivative · entry 3

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,522 shares

Expires 2034-06-04

F2 · derivative.exercise_date: 100% vested.

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 6

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 8,153

Underlying: Common Stock · 8,153 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% vested.

F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 5

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,153 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% vested.

SEC source: 0001415889-25-014865 · form4-05292025_080532.xml · nonDerivative · entry 2

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 7,760

F1 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

SEC source: 0001415889-25-014865 · form4-05292025_080532.xml · nonDerivative · entry 1

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,029

SEC source: 0001415889-25-013949 · form4-05212025_080534.xml · derivative · entry 3

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,503

Underlying: Common Stock · 12,503 shares

Expires 2035-05-19

F3 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-013949 · form4-05212025_080534.xml · nonDerivative · entry 1

Buller Richard E · CIK 0001688319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,108

F1 · shares: Represents 1,029 shares of restricted stock for which risk of forfeiture lapses on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-013950 · form4-05212025_080532.xml · derivative · entry 1

Dalvey David · CIK 0001296457 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-013948 · form4-05212025_080545.xml · derivative · entry 1

NIGON RICHARD · CIK 0001213869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-013946 · form4-05212025_080545.xml · derivative · entry 1

Furcht Leo · CIK 0001775749 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-013945 · form4-05212025_080522.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

SEC source: 0001415889-25-010689 · form4-04152025_080423.xml · nonDerivative · entry 2

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,265,859

SEC source: 0001415889-25-010689 · form4-04152025_080423.xml · nonDerivative · entry 1

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 6

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust #2

Disclosed balance after: 802,742

F1 · ownership.direct: The Reporting Person holds all voting and dispositive power with respect to the securities held by the trusts and is the beneficial owner of these securities.

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 5

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 8,155

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 4

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 45,000

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 3

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,257,704

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 2

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust #1

Disclosed balance after: 948,042

F1 · ownership.direct: The Reporting Person holds all voting and dispositive power with respect to the securities held by the trusts and is the beneficial owner of these securities.

SEC source: 0001415889-25-007006 · form4-03052025_100325.xml · nonDerivative · entry 1

Sullivan Brian F. · CIK 0000940454 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,302,704

SEC source: 0001415889-25-004378 · form4-02182025_090255.xml · derivative · entry 1

Laing Lance G. · CIK 0001716041 · Director · Chief Science Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,962

Underlying: Common Stock · 10,962 shares

Expires 2035-02-13

F1 · derivative.exercise_date: These shares vest in full on February 21, 2025.

SEC source: 0001415889-25-000752 · form4-01062025_090143.xml · derivative · entry 2

Hahne Vicky · CIK 0001716043 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,328

Underlying: Common Stock · 11,328 shares

Expires 2035-01-02

F2 · derivative.exercise_date: Stock options vest and become exercisable in 12 equal installments on the last day of each month following the grant date, beginning on January 31, 2025 and ending on December 31, 2025.